logo
Plus   Neg
Share
Email

Sangamo, Pfizer Report Promising Interim Results With SB-525 Gene Therapy

Sangamo Therapeutics, Inc. (SGMO) and Pfizer, Inc. (PFE) announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. The company said the data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts. Based on the results, the Safety Monitoring Committee recommended cohort expansion at the 3e13 vg/kg dose.

The U.S. FDA has granted Orphan Drug and Fast Track designations to SB-525, which also received Orphan Medicinal Product designation from the European Medicines Agency. SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A new research has found unusual increase in malware, as cyber criminals find new avenues to attack. WatchGuard Technologies on Tuesday released its quarterly Internet Security Report for first quarter. The report says malware detections in the first quarter surged a massive 62% from previous quarter. The... A study has suggested that the risk of dementia is stronger in older adults on the use of anticholinergic drugs, highlighting the importance of reducing exposure to anticholinergic drugs in middle-aged and older people. Anticholinergic drugs work by blocking the action of a neurotransmitter called acetylcholine. This inhibits nerve impulses responsible for involuntary muscle movements. Norway's $1 trillion sovereign wealth fund, the world's largest, has been given the approval to invest again in retail giant Walmart Inc. and miner Rio Tinto plc, among other companies. This follows the Norway central bank's decision to revoke these companies' exclusions from the fund's investments on ethical grounds. Walmart was excluded in 2006 from the pension fund's investments.
Follow RTT